Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Inovio (INO) To Contact Him Directly To Discuss Their Options If you purchased or...
-
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PomDoctor (POM) To Contact Him Directly To Discuss Their Options If you purchased or...
-
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Paysafe (PSFE) To Contact Him Directly To Discuss Their Options If you purchased or...
-
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In TruBridge (TBRG)To Contact Him Directly To Discuss Their Options If you purchased or...
-
Did you buy GEMI Class A common stock and/or securities between September 12, 2025, and February 17, 2026? Affected GEMI Investor Summary Who: Gemini Space Station, Inc. (NASDAQ: GEMI)What:...
-
Did you buy SLNO common stock between March 26, 2025, and November 4, 2025? Affected Soleno Therapeutics, Inc. Investor Summary Who: Soleno Therapeutics, Inc. (NASDAQ: SLNO)What: Securities fraud...
-
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Oracle (ORCL) To Contact Him Directly To Discuss Their Options If you purchased or...
-
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Ultragenyx (RARE) To Contact Him Directly To Discuss Their Options If you purchased or...
-
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Mereo (MREO) To Contact Him Directly To Discuss Their Options If you purchased or...
-
Investors who lost money in SLNO after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.